GE wants to share ideas to acclerate development of ultrasound tech

By Mark Hollmer It’s no secret that General Electric ($GE) has been working aggressively to advance its ultrasound research and development. But now the technology giant is ...

Boston Sci rolls out fresh cardiac products for two international launches

By Mark Hollmer Boston Scientific ($BSX) is revving up for two major international product launches: a new drug-eluting stent system to treat peripheral artery lesions and an updated ...

Private equity owners put for-sale sign on U.K.’s Rosemont

By Tracy Staton Shopping for a drug company that’s adept at making liquid formulas? You’re in luck, because privately held Rosemont Pharmaceuticals is on the block. Owned ...

UPDATED: Hologic says K-V ‘mismanagement’ killing Makena

K-V tells judge forfeiting drug would do the drugmaker in By Eric Palmer K-V Pharmaceuticals ($KV.A) has been desperately trying to create a market for its premature birth drug Makena while ...

Questcor stock reels as feds eye Acthar marketing

By Tracy Staton As if last week’s reimbursement blow to Questcor Pharmaceuticals ($QCOR) wasn’t enough, the company today disclosed that the U.S. government is investigating ...

Moody’s gives pharma a sigh of relief with ‘Worst Is Over’ outlook

By Tracy Staton Here’s a new diagnosis for the pharma industry, courtesy of Moody’s Investors service. “The Worst Is Over,” the research firm pronounced in ...

$1B at stake for Roche in warring Herceptin studies

By Tracy Staton Herceptin will step into the spotlight at this week’s European Society for Medical Oncology meeting. Whether Roche ($RHHBY) will like what happens next isn’t ...

Bayer takes aim at J&J’s Evra with new birth control patch

By Eric Palmer Bayer, already one of the biggest players in the $8 billion a year contraceptive drug market, is aiming to take on Johnson & Johnson ($JNJ) in Europe with a transparent birth ...

Report: Roche’s Zelboraf, BMS’ Yervoy control their segment

By Eric Palmer A new market report says Yervoy from Bristol-Myers Squibb ($BMY) and Zelboraf from Roche ($RHHBY) have sewn up two-thirds of the market for treating advanced malignant melanoma and ...

PhRMA offers help cutting Medicare drug costs, with caveats

By Eric Palmer Big Pharma is willing to do its part to cut the deficit; it would just like to do it in a way that is less painful than some in Washington are suggesting. In a speech ...

Judge lets Gorsky off the hook in Risperdal case

CEO will not have to face a jury in case where 17-year-old boy allegedly grew breasts after taking Risperdal By Eric Palmer Johnson & Johnson ($JNJ) CEO Alex Gorsky has again ...

UPDATED: EU gives recommendation for Regeneron’s Eylea

By Eric Palmer Regeneron Pharmaceuticals ($REGN) has been giving Roche ($RHHBY) fits with its Eylea drug, stealing market share from the Swiss drugmaker’s Lucentis. It ...
Page 20 of 105« First...10...1819202122...304050...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS